Date | Time | Source | Headline | Symbol | Company |
05/21/2024 | 4:55PM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:AVRO | AVROBIO Inc |
05/09/2024 | 4:30PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:AVRO | AVROBIO Inc |
05/06/2024 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:AVRO | AVROBIO Inc |
02/27/2024 | 10:50AM | PR Newswire (US) | Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm | NASDAQ:AVRO | AVROBIO Inc |
02/23/2024 | 4:00PM | Edgar (US Regulatory) | Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:AVRO | AVROBIO Inc |
02/05/2024 | 8:01PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AVRO | AVROBIO Inc |
02/05/2024 | 7:59PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AVRO | AVROBIO Inc |
02/05/2024 | 7:57PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AVRO | AVROBIO Inc |
02/05/2024 | 7:56PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AVRO | AVROBIO Inc |
02/01/2024 | 2:25PM | PR Newswire (US) | Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm | NASDAQ:AVRO | AVROBIO Inc |
01/30/2024 | 4:47PM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:AVRO | AVROBIO Inc |
01/30/2024 | 4:07PM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:AVRO | AVROBIO Inc |
01/30/2024 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AVRO | AVROBIO Inc |
01/30/2024 | 9:05AM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:AVRO | AVROBIO Inc |
01/30/2024 | 8:39AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AVRO | AVROBIO Inc |
01/30/2024 | 8:00AM | Business Wire | AVROBIO and Tectonic Therapeutic Announce Merger | NASDAQ:AVRO | AVROBIO Inc |
11/09/2023 | 4:30PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:AVRO | AVROBIO Inc |
11/03/2023 | 4:15PM | Edgar (US Regulatory) | Form RW - Registration Withdrawal Request | NASDAQ:AVRO | AVROBIO Inc |
08/10/2023 | 4:32PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:AVRO | AVROBIO Inc |
07/12/2023 | 7:13AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AVRO | AVROBIO Inc |
07/12/2023 | 7:00AM | Business Wire | AVROBIO to Explore Strategic Alternatives | NASDAQ:AVRO | AVROBIO Inc |
07/03/2023 | 1:17PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AVRO | AVROBIO Inc |
06/14/2023 | 5:20PM | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) | NASDAQ:AVRO | AVROBIO Inc |
06/12/2023 | 7:20AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:AVRO | AVROBIO Inc |
06/12/2023 | 7:00AM | Business Wire | AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million | NASDAQ:AVRO | AVROBIO Inc |
06/09/2023 | 4:12PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:AVRO | AVROBIO Inc |
06/08/2023 | 4:32PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AVRO | AVROBIO Inc |
06/08/2023 | 4:32PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AVRO | AVROBIO Inc |
06/08/2023 | 4:29PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AVRO | AVROBIO Inc |
06/08/2023 | 4:28PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AVRO | AVROBIO Inc |